ESTRO 2023 - Abstract Book

S1103

Digital Posters

ESTRO 2023

Between 2010 and 2021, 35 patients with isolated local recurrence of resected pancreatic were treated with SBRT. Pancreato-duodenectomy was performed on 25 patients, distal pancreatectomy in 10 cases, all with radical resection (R0). Demographic, clinical and treatment characteristics are shown in Table 1. Median follow-up was 14 months (5.7 - 94.7). Median LC was 30.2 months. One-, 2- and 3-year LC rate was 67.8% (95%CI 47.9 – 81.4), 62.9% (95%CI 42.2 – 77.9) and 46.6% (95%CI 22.4 – 67.7), respectively. According to RECIST criteria, we observed one patient with complete response (2.8%), 7 partial response cases (20%), 14 patients showed disease stability (40%) and 13 (37.2%) had a local progression. Median DPFS was 9.82 months; 1, 2 and 3-year DPFS rate was 44% (95%CI 26.9 – 59.9), 29.3% (95%CI 13.5 – 47.2) and 29.3% (95%CI 13.5 – 47.2). Six patients (17.1%) were alive at the time of analysis and 2 of them (5.7%) had no evidence of local and metastatic disease. Median OS was 15.1 months and 1-, 2- and 3-year OS rate was 67.6% (95%CI 49.1 – 80.6%), 29.9% (95%CI 15.3 – 46.0) and 19.4% (95%CI 7.7 – 35.0), respectively. We did not observe acute and/or late G3 toxicity.

Conclusion SBRT has proven to be a promising and safe therapeutic option in these selected long-survivors patients, in terms of good local control rate and low toxicity profile.

PO-1374 Practice of Radiation Therapy for SCC esophageal cancer in Austria – A Survey of the ÖGRO-GIT-Group

S. Gerum 1 , W. Iglseder 2 , P. Clemens 3 , P. Harl 4 , R. Jaeger 5 , T. Knocke-Abulesz 6 , G. Kurzweil 7 , K. Peterka 8 , I. Reiter 9 , J. Salinger 10 , R. Schmid 11 , S. Schwaiger 12 , H. Stranzl-Lawatsch 13 , C. Venhoda 14 , F. Sedlmayer 15 , F. Roeder 15 1 Landeskrankenhaus Salzburg, Uniklinikum der Paracelsus Medizinischen Universität, , Radiation Oncology, Salzburg, Austria; 2 Universitätsklinik für Radiotherapie und Radio-Onkologie, Landeskrankenhaus Salzburg, Uniklinikum der Paracelsus Medizinischen Universität, Radiotherapy and Radiooncology, Salzburg, Austria; 3 Landeskrankenhaus Feldkirch, Radiation and Radiooncology, Feldkirch, Austria; 4 SMZ – Ost Donauspital der Stadt Wien, Radiation Oncology, Wien, Austria; 5 Medizinische Universität Innsbruck, Radiation and Radiooncology, Innsbruck, Austria; 6 Wiener Gesundheitsverbund Klinik Hietzing, RadiationOncology, Wien, Austria; 7 Salzkammergutklinikum Vöcklabruck, Radiation and Radiationoncology, Vöcklarbruck, Austria; 8 Kaiser-Franz-Josef-Spital / SMZ Süd-Klinik Favoriten, Radiation oncology, Wien, Austria; 9 Landesklinikum Wiener Neustadt, Radiation oncology, Wiener Neustadt, Austria; 10 Universitätsklinikum Krems, Radiation and Radiooncology, Krems an der Donau, Austria; 11 Medizinische Universität Wien, Universitätsklinikum AKH Wien,, Radiation and Radiooncology, Wien, Austria; 12 Klinik Ottakring, Wilhelminenspital der Stadt Wien, Radiation and Radiooncology, Wien, Austria; 13 Comprehensive Cancer Center Graz, Medizinische Universität Graz,, Radiation and Radiooncology, Graz, Austria; 14 Klinikum der Barmherzigen Schwestern, Ordensklinikum Linz, Radiation and Radiooncology, Linz, Austria; 15 Landeskrankenhaus Salzburg, Uniklinikum der Paracelsus Medizinischen Universität, Radiation and Radiooncology, Salzburg, Austria Materials and Methods An anonymous questionnaire (57 items) was sent to all 14 public Austrian radiation oncology departments. Results were analyzed descriptively and compared to two major international guidelines (NCCN and ESMO) in their latest versions Results The response rate was 93%. Median number of patients per center and year was 13 (5-30). All centers indicated pretreatment multidisciplinary evaluation. Work-up generally included endoscopy and cross sectional imaging of chest/abdomen (mainly CT). EUS was used by 61% and PET-CT by 54%. Functional lung testing was reported only by 46%. No center indicated the prophylactic placement of feeding tubes or stents. All centers use IMRT in conventional Purpose or Objective To evaluate the patterns of care of chemoradiation for squamous cell esophageal cancer in Austria